The Data Management and Biostatistics Core (DMBC) will serve as a resource and collaborator for all projects and cores related to this program project. Specifically the DMBC will: (1) consult on the design of all projects and in the application of appropriate statistical and methodological techniques;(2) lead and collaborate in data analysis and report preparation for all cores and projects, especially in the analysis of associations among longitudinal growth/decline patterns of all disease markers across the individual projects;(3) coordinate and implement participant scheduling program across all projects and cores;(4) continue our collaboration with the WU Center for Biomedical Informatics (CBMI) to complete the transition to our bioinformatics platforms, make data collected by ACS cores and projects available to all ACS investigators, and insure the quality control of all analysis data sets for publications;(5) collaborate in the design of all forms to be used;(6) develop, apply, and implement statistical data analysis techniques appropriate for addressing the scientific aims of the program project.
The Data Management and Biostatistics Core (DMBC) provides design, analyses, and data management resources to support all the ACS projects and cores. The relevance of the DMBC is that ACS addresses crucial public health questions to identify the earliest possible biomarker changes for Alzheimer's disease and dementia so that prevention and/or treatment can be started early.
|Schindler, Suzanne E; Sutphen, Courtney L; Teunissen, Charlotte et al. (2018) Upward drift in cerebrospinal fluid amyloid ? 42 assay values for more than 10 years. Alzheimers Dement 14:62-70|
|Sato, Chihiro; Barthélemy, Nicolas R; Mawuenyega, Kwasi G et al. (2018) Tau Kinetics in Neurons and the Human Central Nervous System. Neuron 98:861-864|
|Millar, Peter R; Balota, David A; Bishara, Anthony J et al. (2018) Multinomial models reveal deficits of two distinct controlled retrieval processes in aging and very mild Alzheimer disease. Mem Cognit 46:1058-1075|
|Babulal, Ganesh M; Chen, Suzie; Williams, Monique M et al. (2018) Depression and Alzheimer's Disease Biomarkers Predict Driving Decline. J Alzheimers Dis 66:1213-1221|
|Vlassenko, Andrei G; Gordon, Brian A; Goyal, Manu S et al. (2018) Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. Neurobiol Aging 67:95-98|
|Gangishetti, Umesh; Christina Howell, J; Perrin, Richard J et al. (2018) Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimers Res Ther 10:98|
|Stout, Sarah H; Babulal, Ganesh M; Ma, Chunyu et al. (2018) Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers. Alzheimers Dement 14:610-616|
|Roe, Catherine M; Babulal, Ganesh M; Stout, Sarah H et al. (2018) Using the A/T/N Framework to Examine Driving in Preclinical AD. Geriatrics (Basel) 3:|
|Day, Gregory S; Musiek, Erik S; Morris, John C (2018) Rapidly Progressive Dementia in the Outpatient Clinic: More Than Prions. Alzheimer Dis Assoc Disord 32:291-297|
|Chen, Jason A; Fears, Scott C; Jasinska, Anna J et al. (2018) Neurodegenerative disease biomarkers A?1-40, A?1-42, tau, and p-tau181 in the vervet monkey cerebrospinal fluid: Relation to normal aging, genetic influences, and cerebral amyloid angiopathy. Brain Behav 8:e00903|
Showing the most recent 10 out of 352 publications